MolecuLight Inc.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Jul 8, 2026

Completed

A 12-week, Prospective, Parallel Arm, Randomized Controlled Trial (RCT) Comparing Wound Area Reduction of Non-healing Diabetic Foot Ulcers With MolecuLight i:X Used in Standard of Care Compared to Standard of Care Alone

Jul 3, 2026

Completed

A Prospective, Clinical Evaluation of the MolecuLightDX+ With OxySight Module to Observe the Clinical Utility of Tissue Oxygenation, Bacterial Fluorescence and Thermal Signatures

Earlier

Jun 26, 2026TrialEvaluation of the MolecuLightDX Device in the Measurement of Surface Wounds in Patients

Jun 26, 2026TrialSpectroscopic Assessment of Autofluorescent Signatures of Tissue in and Around Wounds Identified by MolecuLightDX Imaging Device

Jun 26, 2026TrialA Prospective, Single-blind, Clinical Evaluation of the MolecuLight DX in Combination With Biofilm Based Wound Care for the Identification of Biofilm Containing Wounds

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)